These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24184129)

  • 21. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
    Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
    J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.
    Gilbert C; Boivin G
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4860-6. PubMed ID: 16304146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
    Fischer L; Sampaio KL; Jahn G; Hamprecht K; Göhring K
    J Clin Virol; 2015 Aug; 69():150-5. PubMed ID: 26209398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance.
    Pérez JL
    Microbiologia; 1997 Sep; 13(3):343-52. PubMed ID: 9353754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir.
    Bounaadja L; Piret J; Goyette N; Boivin G
    J Clin Virol; 2013 Sep; 58(1):279-82. PubMed ID: 23871165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.
    Boivin G; Goyette N; Gilbert C; Covington E
    J Med Virol; 2005 Nov; 77(3):425-9. PubMed ID: 16173018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
    Chou S; Marousek GI
    J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
    Cihlar T; Fuller MD; Cherrington JM
    J Virol; 1998 Jul; 72(7):5927-36. PubMed ID: 9621055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
    Drew WL; Miner RC; Marousek GI; Chou S
    J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mechanism of drug-resistance in human cytomegalovirus].
    Eizuru Y
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():476-9. PubMed ID: 17455666
    [No Abstract]   [Full Text] [Related]  

  • 32. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
    Cihlar T; Fuller MD; Mulato AS; Cherrington JM
    Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus.
    Posthuma CC; van der Beek MT; van der Blij-de Brouwer CS; van der Heiden PL; Marijt EW; Spaan WJ; Claas EC; Nederstigt C; Vossen AC; Snijder EJ; Kroes AC
    J Clin Virol; 2011 May; 51(1):25-30. PubMed ID: 21388868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase.
    Mousavi-Jazi M; Schloss L; Wahren B; Brytting M
    J Clin Virol; 2003 Apr; 26(3):301-6. PubMed ID: 12637079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
    Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
    J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers.
    Chen H; Lawler JL; Filman DJ; Hogle JM; Coen DM
    mBio; 2021 Feb; 12(1):. PubMed ID: 33563814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
    Martin M; Goyette N; Ives J; Boivin G
    J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome.
    Martin M; Gilbert C; Covington E; Boivin G
    J Infect Dis; 2006 Sep; 194(5):579-83. PubMed ID: 16897654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
    Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
    J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
    Chou S
    Antiviral Res; 2017 Feb; 138():57-60. PubMed ID: 27940027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.